BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 31468291)

  • 1. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.
    Yan F; Wang W; Zhang J
    Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291
    [No Abstract]   [Full Text] [Related]  

  • 2. Keeping our eyes on CRISPR: the "Atlas" of gene editing.
    Wang W; Hou J; Zheng N; Wang X; Zhang J
    Cell Biol Toxicol; 2019 Aug; 35(4):285-288. PubMed ID: 31165372
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiplexed conditional genome editing with Cas12a in
    Port F; Starostecka M; Boutros M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22890-22899. PubMed ID: 32843348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErCas12a CRISPR-MAD7 for Model Generation in Human Cells, Mice, and Rats.
    Liu Z; Schiel JA; Maksimova E; Strezoska Ž; Zhao G; Anderson EM; Wu Y; Warren J; Bartels A; van Brabant Smith A; Lowe CE; Forbes KP
    CRISPR J; 2020 Apr; 3(2):97-108. PubMed ID: 32315227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Type V-A CRISPR Effectors Are Active Nucleases with Expanded Targeting Capabilities.
    Aliaga Goltsman DS; Alexander LM; Devoto AE; Albers JB; Liu J; Butterfield CN; Brown CT; Thomas BC
    CRISPR J; 2020 Dec; 3(6):454-461. PubMed ID: 33146573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Survey of Genome Editing Activity for 16 Cas12a Orthologs.
    Zetsche B; Abudayyeh OO; Gootenberg JS; Scott DA; Zhang F
    Keio J Med; 2020 Sep; 69(3):59-65. PubMed ID: 31723075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of Cas9 and single-guided RNAs in
    Qiao J; Li W; Lin S; Sun W; Ma L; Liu Y
    Commun Biol; 2019; 2():161. PubMed ID: 31069270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
    O'Connell MR
    J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.
    Yang H; Patel DJ
    Nat Chem Biol; 2024 Jun; 20(6):673-688. PubMed ID: 38702571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the Biologist's Toolkit with CRISPR-Cas9.
    Sternberg SH; Doudna JA
    Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Battling CRISPR-Cas9 off-target genome editing.
    Li D; Zhou H; Zeng X
    Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-CRISPR proteins: Counterattack of phages on bacterial defense (CRISPR/Cas) system.
    Chaudhary K; Chattopadhyay A; Pratap D
    J Cell Physiol; 2018 Jan; 233(1):57-59. PubMed ID: 28247934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing off-target effects in CRISPR-Cas9 genome editing.
    Chen SJ
    Cell Biol Toxicol; 2019 Oct; 35(5):399-401. PubMed ID: 31317359
    [No Abstract]   [Full Text] [Related]  

  • 18. The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks.
    Hajizadeh Dastjerdi A; Newman A; Burgio G
    BioDrugs; 2019 Oct; 33(5):503-513. PubMed ID: 31385197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the scope of plant genome engineering with Cas12a orthologs and highly multiplexable editing systems.
    Zhang Y; Ren Q; Tang X; Liu S; Malzahn AA; Zhou J; Wang J; Yin D; Pan C; Yuan M; Huang L; Yang H; Zhao Y; Fang Q; Zheng X; Tian L; Cheng Y; Le Y; McCoy B; Franklin L; Selengut JD; Mount SM; Que Q; Zhang Y; Qi Y
    Nat Commun; 2021 Mar; 12(1):1944. PubMed ID: 33782402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome editing in plants with MAD7 nuclease.
    Lin Q; Zhu Z; Liu G; Sun C; Lin D; Xue C; Li S; Zhang D; Gao C; Wang Y; Qiu JL
    J Genet Genomics; 2021 Jun; 48(6):444-451. PubMed ID: 34120856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.